tiprankstipranks
Evotec AG Posts Modest Revenue Growth Amidst Cost Challenges
Company Announcements

Evotec AG Posts Modest Revenue Growth Amidst Cost Challenges

Evotec AG (EVO) has released an update.

Don't Miss our Black Friday Offers:

Evotec AG reports a slight 2% revenue growth to €390.8 million in the first half of 2024, driven by a 50% increase in Just-Evotec Biologics revenues, despite a 7% decrease in the Shared R&D segment. The company faces increased costs leading to an adjusted EBITDA of €(0.5) million, down from €33.9 million in the previous year, and has refined its full-year revenue guidance to €790 – 820 million. Additionally, Evotec announces several strategic partnerships and a new CEO, Dr. Christian Wojczewski, to navigate through a challenging market environment.

For further insights into EVO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyAmazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
TheFlyEvotec takes notice of Halozyme withdrawal, convicted in standalone strategy
TheFlyEvotec falls 21% to $4.20 after Halozyme withdraws acquisition proposal
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App